Circulating soluble receptor for advanced glycation end products is inversely correlated to oxidized low-density lipoproteins in asymptomatic subjects

Journal of International Medical Research

Volumn 40, Issue 5, 2012, Pages 1878-1883

  Kotani, Kazuhiko ^a,b   Caccavello, R ^b   Taniguchi, N ^a   Gugliucci, A ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b TOURO UNIVERSITY CALIFORNIA   (United States)

Author keywords

Advanced glycation end products; Atherosclerosis; Biomarker; Malondialdehyde modified low density lipoprotein; Oxidative stress; Oxidized lipoprotein

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; BIOLOGICAL MARKER; IMMUNOGLOBULIN RECEPTOR;

AGED; ARTICLE; ASYMPTOMATIC DISEASE; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL ARTICLE; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; PROTEIN BLOOD LEVEL; BLOOD; MIDDLE AGED;

AGED; ASYMPTOMATIC DISEASES; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC;

EID: 84880623626     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/030006051204000527     Document Type: Article

References (22)

1. Steinberg D: Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272: 20963-20966.
2. Holvoet P: Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh K Acad Geneeskd Belg 2008; 70: 193-219.
3. Kondo A, Muranaka Y, Ohta I, et al: Relationship between triglyceride concentrations and LDL size evaluated by malondialdehyde-modified LDL. Clin Chem 2001; 47: 893-900.
4. Cerami A, Vlassara H, Brownlee M: Role of nonenzymatic glycosylation in atherogenesis. J Cell Biochem 1986; 30: 111-120.
5. Falcone C, Emanuele E, D’Angelo A, et al: Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005; 25: 1032-1037.
6. Yan SF, Ramasamy R, Schmidt AM: Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 2008; 4: 285-293.
7. Park IH, Yeon SI, Youn JH, et al: Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol Immunol 2004; 40: 1203-1211.
8. Norata GD, Garlaschelli K, Grigore L, et al: Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr Metab Cardiovasc Dis 2009; 19: 129-134.
9. Sun L, Ishida T, Yasuda T, et al: RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovasc Res 2009; 82: 371-381.
10. Tan KC, Shiu SW, Chow WS, et al: Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006; 49: 2756-2762.
11. Imanaga Y, Sakata N, Takebayashi S, et al: In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human atherosclerotic plaques. Atherosclerosis 2000; 150: 343-355.
12. Yamagishi S, Adachi H, Nakamura K, et al: Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006; 55: 1227-1231.
13. Nakamura K, Yamagishi S, Adachi H, et al: Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc Res 2008; 76: 52-56.
14. Tam XH, Shiu SW, Leng L, et al: Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. Clin Sci (Lond) 2011; 120: 81-89.
15. Devangelio E, Santilli F, Formoso G, et al: Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med 2007; 43: 511-518.
16. Schmidt AM, Yan SD, Yan SF, et al: The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000; 1498: 99-111.
17. Basta G: Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008; 196: 9-21.
18. Jang Y, Kim JY, Kang SM, et al: Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metabolism 2007; 56: 199-205.
19. Gaens KH, Ferreira I, van der Kallen CJ, et al: Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J Clin Endocrinol Metab 2009; 94: 5174-5180.
20. Vincent HK, Taylor AG: Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond) 2006; 30: 400-418.
21. Lumeng CN, Saltiel AR: Inflammatory links between obesity and metabolic disease. J Clin Invest 2011; 121: 2111-2117.
22. Unoki H, Bujo H, Yamagishi S, et al: Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes. Diabetes Res Clin Pract 2007; 76: 236-244.